Healthcare
ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI
LYON, France, July 03, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the expiration of Sanofi’s three-year exclusive right to negotiate a partnership agreement for the development of M1Pram1.
About this update from Adocia Sa
LYON, France, July 03, 2026--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership agreement for the development of M1Pram1. "Although no GLP-1 therapy is currently approved for type 1 diabetes, the rise of GLP-1 therapies has reshaped the obesity treatment landscape. We will continue to assess the opportunity for M1Pram as new treatments continue to evolve. In the meantime, we are focusing on the development of our metabolic peptide delivery platforms, particularly BioChaperone®, the most strategic since it addresses the market's recent interest in co-formulations and multi-dose formulations," said Olivier Soula, Chief Executive Officer and Co-founder of Adocia. M1Pram is a fixed combination of insulin and amylin analogs aimed at addressing the unmet medical need of obesity in insulin-dependent individuals, in particular people suffering from type 1 diabetes. In July 2023, Adocia granted Sanofi an exclusive right to negotiate a partnership on M1Pram in return for a payment of €10 million1. Following the expiration of this three-year exclusivity agreement, Adocia retains the global rights to M1Pram. During the Phase 2a trial, M1Pram demonstrated a significant reduction in body weight (5.56 kg for participants with a BMI2 over 30 kg/m², after 16 weeks) compared to insulin lispro among individuals with type 1 diabetes. While GLP-1 have transformed obesity management, these treatments are currently not approved for this population. Alongside the weight reduction, M1Pram also enabled a 21% reduction in prandial insulin doses while maintaining effective glycemic control, without increasing the risk of hypoglycemia. Given its current priorities, Adocia decided to put on hold the development of M1Pram. Adocia will continue to evaluate the path forward for M1Pram as the type 1 diabetes treatment landscape continues to evolve. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on...